Tezepelumab Granted Orphan Drug Status for Eosinophilic Esophagitis
Eosinophilic Esophagitis Gastroenterology General News

Tezepelumab Granted Orphan Drug Status for Eosinophilic Esophagitis

The Food and Drug Administration (FDA) has granted Orphan Drug designation to tezepelumab for the treatment of eosinophilic esophagitis. Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, an…